Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02827747

The Role of Antioxidant Supplementation in Keratoconus Patients

The Role of Antioxidants in Keratoconus Patients-A Randomized Controlled Trial of Oral Supplementation of Glutathione, Vitamin A, Vitamin C and Vitamin E

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
University of Miami · Academic / Other
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

Keratoconus is the most common primary cornea ectasia, where the cornea undergoes structural changes, leading to loss of tissue integrity and vision loss. The prevalence of Keratoconus is 1:2000 in the general population. Oxidative stress has been thought to have a major effect in the disease pathogenesis of Keratoconus. In vitro studies have shown increase in metabolites related to oxidative stress in Keratoconus disease, and that Keratoconus cells undergo increased oxidative stress and tissue damage. Animal models have shown a therapeutic effect of Vitamin C (ascorbate) in corneal wound healing. Glutathione and Vitamins A, C, and E are important antioxidants in the human body. To this date, the role of systemic antioxidant supplementation in Keratoconus patients has yet to be studied. In addition, it has yet to be established as to whether there is a correlation between serum antioxidant levels, and the severity of disease in the Keratoconus patient. The investigators propose to investigate the plasma levels of antioxidants in relation to disease severity. The investigators will also investigate the role of antioxidant supplementation-consisting of parenteral Glutathione (GSH), and Vitamins A, C and E-in delaying the disease progression in Keratoconus.

Conditions

Interventions

TypeNameDescription
OTHERAntioxidants (Vitamins A,C,E) plus GSHStudy medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
OTHERPlaceboPlacebo pill
DIETARY_SUPPLEMENTCentrumCentrum
COMBINATION_PRODUCTDietary SourcesFrom dietary sources of vitamins.

Timeline

Start date
2021-08-01
Primary completion
2022-07-01
Completion
2023-03-01
First posted
2016-07-11
Last updated
2021-08-16

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT02827747. Inclusion in this directory is not an endorsement.

The Role of Antioxidant Supplementation in Keratoconus Patients (NCT02827747) · Clinical Trials Directory